A2A adenosine receptor overexpression and functionality, as well as TNF-α levels, correlate with motor symptoms in Parkinson’s disease

Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?

(2008) Joseph Jankovic   ANNALS OF NEUROLOGY

Potential therapeutic targets for Parkinson's disease

(2008) Jon Stoessl   EXPERT OPINION ON THERAPEUTIC TARGETS

Purinergic signalling and disorders of the central nervous system

(2008) Geoffrey Burnstock   NATURE REVIEWS DRUG DISCOVERY

Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson’s disease

(2008) Jacobus P. Petzer et al.   Neurotherapeutics

Adenosine A2A receptors in Parkinson’s disease treatment

(2008) Marek Cieślak et al.   Purinergic Signalling

Inflammation as a causative factor in the aetiology of Parkinson's disease

(2007) P S Whitton   BRITISH JOURNAL OF PHARMACOLOGY

Adenosine as a neuromodulator in neurological diseases

(2007) D BOISON   CURRENT OPINION IN PHARMACOLOGY